Skip to main content
. 2022 Aug 29;16(20):3587–3605. doi: 10.1002/1878-0261.13304

Fig. 5.

Fig. 5

The HES1 pharmacologic inhibitor JI130 suppress FN‐RMS cell growth in vitro and in vivo. (A) The Hes family BHLH transcription factor 1 (HES1) inhibitor JI130 is effective against RD (left), SMS‐CTR (middle), and Rh36 (right) fusion‐negative rhabdomyosarcoma (FN‐RMS) cells at low nanomolar concentrations in vitro. See insets for half‐maximal inhibitory concentration (IC50) values. IC50 determined by non‐linear regression; error bars indicate standard deviation (SD). n = 3 (B) JI130 is effective at limiting RD xenograft tumor growth as assessed by measuring calculated tumor volume over time. See Section 2 for details. Statistical significance determined by multiple unpaired t‐test with Welch's correction; control n = 13, treated n = 9. (C) H&E staining of vehicle (DMSO)‐treated and JI130‐treated tumors; control n = 9, treated n = 10. (D) Immunohistochemistry (IHC) staining for myogenic differentiation 1 (MYOD1) in DMSO‐treated and JI130‐treated tumors; control n = 9, treated n = 10. (E) imagej quantitation of MYOD1 staining intensity of tumor sections from (D). Horizontal bars indicate mean with standard error of the mean (SEM). Statistical significance determined by unpaired t‐test with Welch's correction; control n = 9, treated n = 10. Images are 200× total magnification with scale bars representing 100 μm for all images in this figure. *P < 0.05; **P < 0.01.